髓外病变——多发性骨髓瘤的致命弱点?
尽管治疗进步,髓外病变(EMD)仍是多发性骨髓瘤的侵袭性形式,预后差;真性EMD(浆细胞瘤完全独立于骨骼)预后尤其差。其发病机制涉及黏附分子丢失、遗传与表观遗传改变及微环境类实体瘤结构。先进影像和免疫治疗改善了检测与结局,但仍需针对真性EMD的前瞻性研究。
要点
- 真性EMD(浆细胞瘤完全独立于骨骼)预后尤其差。
- EMD发病涉及黏附分子丢失、遗传与表观遗传改变及微环境类实体瘤结构。
- 先进影像与免疫治疗改善了检测和结局,但真性EMD仍需前瞻性研究。
核心结论
- 髓外病变仍是多发性骨髓瘤的侵袭性形式,与不良结局相关,真性EMD预后尤其差。
主要发现
- EMD发病机制涉及黏附分子丢失、异质性遗传与表观遗传改变及微环境中的类实体瘤结构。
- 先进影像技术改善了EMD检测,免疫治疗带来了更有希望的结局与方案。
临床怎么用
- 应关注真性EMD患者,其预后尤其差,需更积极诊疗策略。
- 先进影像技术有助于EMD检测,免疫治疗为改善结局提供可能。
局限性
- 仍需更多专门针对真性EMD的前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion molecules, heterogeneous genetic and epigenetic changes, and a solid tumor-like architecture within the microenvironment. Although the introduction of advanced imaging techniques and immunotherapy has led to improved detection and more promising outcomes and regimens, respectively, more prospective studies dedicated to true EMD are needed.
引用
- Kumar S, Richter J, Usmani SZ, et al. Extramedullary Disease-Achilles Heel in Myeloma? Am J Hematol. 2025. PMID: 41462032. doi:10.1002/ajh.70138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。